(secondQuint)Thalidomide in Treating Patients With Relapsed or Progressive Systemic Mastocytosis.

 OBJECTIVES: Primary - Determine the objective response rate at 6 months in patients with systemic mastocytosis treated with thalidomide.

 Secondary - Determine the tolerability of this drug in these patients.

 OUTLINE: This is a multicenter study.

 Patients receive oral thalidomide once daily for 6 months in the absence of disease progression.

.

 Thalidomide in Treating Patients With Relapsed or Progressive Systemic Mastocytosis@highlight

RATIONALE: Thalidomide may stop the growth of systemic mastocytosis by blocking blood flow to the disease.

 PURPOSE: This phase II trial is studying how well thalidomide works in treating patients with relapsed or progressive systemic mastocytosis.

